Top 20 Biopharma M&A of 2021 by Total Deal Value

Shots: Biopharma merger and acquisition activity continued under the radar with smaller deals through 2021. Despite the absence of eagerly-awaited mega-merger, there were a number of deals above $1 billion. CSL Limited holds the top rank by acquiring Vifor Pharma among the top 20 acquisitions with a total deal value of $11.7B. CSL adds 10…

ByPrince GiriJanuary 20, 20220Comments

INSIGHTS+

Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2022 Based on Therapeutic Areas

Shots: The 40th Annual J.P. Morgan Healthcare Conference took place virtually on Jan 10-13, 2022. The premier conference is the most extensive and most informative health care investment symposium in the Healthcare and pharma sector, which connects global leaders, emerging companies, innovative technology creators, and members of the investment community Considering the top biopharma companies…

BySenior EditorJanuary 19, 20220Comments

VIEWPOINTS

PharmaShots Interview: GSK’s Thomas C. Corbridge Shares Insights on the New Survey Data for Severe Eosinophilic Asthma Patients

In an interview with PharmaShots, Thomas C. Corbridge, US Senior Medical Lead at GSK shares his views on the new survey and demonstrated dissatisfaction with the asthma treatment paradigm Shots: The survey was commissioned by GSK and conducted by The Harris Poll in 100 patients aged ≥18yrs. showed that a majority of SEA patients and physicians are concerned about the current state…

BySenior EditorJanuary 18, 20220Comments

VIEWPOINTS

PharmaShots Interview: Janssen’s Nikki Longwell Shares Insights on the National Biologic Coordinators Day

In an interview with PharmaShots, Nikki Longwell, Sr. Director, Medical Science Liaisons, Immunology at Janssen shares her views on the launch of the National Biologic Coordinators Day supporting the needs of people living with autoimmune diseases Shots: The company has launched the first national awareness day “National Biologic Coordinators Day” on Nov 1 which is also known as a day…

BySenior EditorJanuary 17, 20220Comments

INSIGHTS+

Deal Maker of the Year 2021 (Part 02)

Shots: Roche was at the top with 32 deals for a total announced deal value of ~$25.83B with multiple biopharma companies The highest value deal was Roche’s AI pact with Recursion valued at up to ~$12B to identify and develop up to 40 new medications in neuroscience and oncology indications Pfizer and Merck are two…

BySenior EditorJanuary 13, 20220Comments

VIEWPOINTS

PharmaShots Interview: Medicago’s Brian Ward Shares Insights on the Data of Plant-Based COVID-19 Vaccine

In an interview with PharmaShots, Brian Ward, Medical Officer at Medicago shares his views on the P-III study of plant-based COVID-19 vaccine in combination with GSK’s pandemic adjuvant for the treatment of COVID-19 Shots: The company reported efficacy and safety results from the P-III study of Medicago’s plant-based COVID-19 vaccine candidate + GSK’s pandemic adjuvant in ~24,000 adults aged ≥18yrs. across Canada, US, UK,…

BySenior EditorJanuary 12, 20220Comments

VIEWPOINTS

PharmaShots Interview: Insmed’s Martina Flammer Shares Insights on New Affordable Drugs for Rare Diseases

In an interview with PharmaShots, Martina Flammer, Chief Medical Officer at Insmed share her views on the R&D continuum to develop new drugs for rare diseases and also highlights its business pillars Shots: The idea of the continuum is that all department works together to develop the drugs which will be helpful not only for the company but for patients too In…

BySenior EditorJanuary 11, 20220Comments

SPOTLIGHT

Spotlight Interview with Chris Dokomajilar, CEO and Founder of DealForma

On January 10, 2022, PharmaShots has launched a new section in its interview series: Spotlight - Company of the Month Company of the month is our new exclusive feature under which we are interviewing the key leaders of the start-ups that are providing fierce solutions. We pick one company every month and interview them about…

BySenior EditorJanuary 10, 20220Comments

INSIGHTS+

Deal Maker of the Year 2021 (Part 01)

Shots: AstraZeneca and Roche were the top dealmakers completed 33 deals with multiple pharma and biotech companies and universities for a total deal value of $6.2B & $25.83B The highest value deal was AstraZeneca’s partnership with Ionis for the development and commercialization of Eplontersen signed on Dec. 7, 2021. Merck and Pfizer are among the…

BySenior EditorJanuary 7, 20220Comments

INSIGHTS+

Insights+ Key Biosimilars Events of December 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of December, Samsung Bioepis presented five-year follow-up results of…

BySenior EditorJanuary 6, 20220Comments

Top 20 Biopharma M&A of 2021 by Total Deal Value

Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2022 Based on Therapeutic Areas

PharmaShots Interview: GSK’s Thomas C. Corbridge Shares Insights on the New Survey Data for Severe Eosinophilic Asthma Patients

PharmaShots Interview: Janssen’s Nikki Longwell Shares Insights on the National Biologic Coordinators Day

Deal Maker of the Year 2021 (Part 02)

PharmaShots Interview: Medicago’s Brian Ward Shares Insights on the Data of Plant-Based COVID-19 Vaccine

PharmaShots Interview: Insmed’s Martina Flammer Shares Insights on New Affordable Drugs for Rare Diseases

Spotlight Interview with Chris Dokomajilar, CEO and Founder of DealForma

Deal Maker of the Year 2021 (Part 01)

Insights+ Key Biosimilars Events of December 2021

Contact US

OUR INFORMATION

FOLLW US

FOLLW US

Sign Up to Our Newsletter